Posted on Apr 29, 2021, 5:28 PMUpdated Apr 29, 2021, 5:47 PM
The Covid will have definitely made the happiness of the outsiders. The American biotech Novavax could thus, in the summer, come to swell the ranks of the suppliers of vaccines with a theoretical production capacity of 2 billion doses. Her product is in Phase III trial on 30,000 people in the United States and Mexico and she hopes to get the green light from the American authorities next month. On the European side, it has not yet started negotiations but already has a contract for 60 million doses with Great Britain.
While on the starting line with Moderna, BioNTech and other AstraZeneca, Novavax was left behind by its competitors who took control of factories, raw materials and equipment, creating a situation of tension or even shortage. that she was not in the best position to face. Indeed, while all its competitors have embarked on the race, with pockets full to varying degrees, Novavax, which in 33 years of existence has not succeeded in marketing a single product, took the start with a cash flow. barely allowing him to live six months.